Ribozyme-mediated cleavage of bcr-abl mRNA has been shown to be associ
ated with the concomitant cleavage of bcr mRNA. The possible role of t
his ribozyme as a clinical therapeutic constrained us to improve its t
arget specificity. Consequently, three modified ribozymes (Rz7-9) were
created, each carrying a single base mismatch in the sequence immedia
tely 5' of the cleavage site, while a fourth ribozyme (Rz10) was targe
ted to a nearby site. Each was compared with the parent ribozyme for i
ts ability to cleave synthetic bcr-abl and bcr substrates, and it was
shown that alteration of the second base 5' of the cleavage site creat
ed a ribozyme with significantly improved specificity for its substrat
e. Rz10 was shown to exclusively act on bcr-abl, but the efficiency of
cleavage was reduced compared to that shown by ribozymes 6, 8, and 9.